The Cross-talk Relationship between Metformin and Gut Microbiota

Background: Metformin is the first-line oral therapy for type 2 diabetes mellitus. However, its mode of action is poorly defined. There is an increasing awareness regarding the cross talk of gut microbiota and metformin. The current review aimed to assess the bidirectional relationship between metfo...

Full description

Bibliographic Details
Main Authors: Hyder O. Mirghani. MD, M.Sc.
Format: Article
Language:English
Published: Knowledge E 2020-12-01
Series:Sudan Journal of Medical Sciences
Subjects:
Online Access:https://doi.org/10.18502/sjms.v15i4.8165
_version_ 1818718715207745536
author Hyder O. Mirghani. MD
M.Sc.
author_facet Hyder O. Mirghani. MD
M.Sc.
author_sort Hyder O. Mirghani. MD
collection DOAJ
description Background: Metformin is the first-line oral therapy for type 2 diabetes mellitus. However, its mode of action is poorly defined. There is an increasing awareness regarding the cross talk of gut microbiota and metformin. The current review aimed to assess the bidirectional relationship between metformin and gut microbiota. Methods: Electronic search was conducted in Pub Med and the first 100 articles in Google Scholar published until November 2019. However, only randomized controlled trials on humans published in the English language were included. The terms “gut microbiota,” “gut flora "and “ metformin” were as keywords to perform the search. Although 124 articles were retrieved, only six met the inclusion criteria of the study. Results: Of the six full texts of randomized controlled trials included in the study, two-thirds were published in Europe, one in the USA, and one in China. Six hundred-thirty five patients were included and the duration of the studies ranged from seven days to six months. The studies concluded that microbiota modulates some metformin actions on plasma glucose; while metformin enhances the abundance of microbiota that positively affect insulin resistance and plasma glucose. Conclusion: The current review showed that microbiota dysbiosis may mediate metformin antidiabetic effects. Whereas metformin shifted the gut microbiota toward the beneficial species ameliorating insulin resistance. The present study might provide insights into a novel therapeutic approach to treat type 2 diabetes mellitus.
first_indexed 2024-12-17T19:55:27Z
format Article
id doaj.art-a350fb79a4b24fc79814af7f80dbd0e7
institution Directory Open Access Journal
issn 1858-5051
language English
last_indexed 2024-12-17T19:55:27Z
publishDate 2020-12-01
publisher Knowledge E
record_format Article
series Sudan Journal of Medical Sciences
spelling doaj.art-a350fb79a4b24fc79814af7f80dbd0e72022-12-21T21:34:37ZengKnowledge ESudan Journal of Medical Sciences1858-50512020-12-011542543010.18502/sjms.v15i4.8165sjms.v15i4.8165The Cross-talk Relationship between Metformin and Gut MicrobiotaHyder O. Mirghani. MD0M.Sc.1Associate Professor of Internal Medicine and Endocrine, Medical Department, Faculty of Medicine, University of Tabuk, KSAAssociate Professor of Internal Medicine and Endocrine, Medical Department, Faculty of Medicine, University of Tabuk, KSABackground: Metformin is the first-line oral therapy for type 2 diabetes mellitus. However, its mode of action is poorly defined. There is an increasing awareness regarding the cross talk of gut microbiota and metformin. The current review aimed to assess the bidirectional relationship between metformin and gut microbiota. Methods: Electronic search was conducted in Pub Med and the first 100 articles in Google Scholar published until November 2019. However, only randomized controlled trials on humans published in the English language were included. The terms “gut microbiota,” “gut flora "and “ metformin” were as keywords to perform the search. Although 124 articles were retrieved, only six met the inclusion criteria of the study. Results: Of the six full texts of randomized controlled trials included in the study, two-thirds were published in Europe, one in the USA, and one in China. Six hundred-thirty five patients were included and the duration of the studies ranged from seven days to six months. The studies concluded that microbiota modulates some metformin actions on plasma glucose; while metformin enhances the abundance of microbiota that positively affect insulin resistance and plasma glucose. Conclusion: The current review showed that microbiota dysbiosis may mediate metformin antidiabetic effects. Whereas metformin shifted the gut microbiota toward the beneficial species ameliorating insulin resistance. The present study might provide insights into a novel therapeutic approach to treat type 2 diabetes mellitus.https://doi.org/10.18502/sjms.v15i4.8165gut microbiota, metformin, type 2 diabetes
spellingShingle Hyder O. Mirghani. MD
M.Sc.
The Cross-talk Relationship between Metformin and Gut Microbiota
Sudan Journal of Medical Sciences
gut microbiota, metformin, type 2 diabetes
title The Cross-talk Relationship between Metformin and Gut Microbiota
title_full The Cross-talk Relationship between Metformin and Gut Microbiota
title_fullStr The Cross-talk Relationship between Metformin and Gut Microbiota
title_full_unstemmed The Cross-talk Relationship between Metformin and Gut Microbiota
title_short The Cross-talk Relationship between Metformin and Gut Microbiota
title_sort cross talk relationship between metformin and gut microbiota
topic gut microbiota, metformin, type 2 diabetes
url https://doi.org/10.18502/sjms.v15i4.8165
work_keys_str_mv AT hyderomirghanimd thecrosstalkrelationshipbetweenmetforminandgutmicrobiota
AT msc thecrosstalkrelationshipbetweenmetforminandgutmicrobiota
AT hyderomirghanimd crosstalkrelationshipbetweenmetforminandgutmicrobiota
AT msc crosstalkrelationshipbetweenmetforminandgutmicrobiota